Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
ClinicalTrials.gov Identifier:
NCT01397825
First received: July 17, 2011
Last updated: November 17, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2016
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: November 17, 2016